COMPASS Pathways plc Stock Price

A late-stage psilocybin therapy from COMPASS Pathways is moving closer to a possible regulatory decision, and the company is already building the clinics-and-insurance playbook to speed up adoption if it clears the bar. The bigger upside is an expansion into PTSD, but delays, tougher oversight, and the need to raise more cash could still change the outcome.Read more

COMPASS Pathways is racing to bring a psilocybin-based treatment into late-stage testing, and the near-term story hinges on whether those results hold up and regulators stay supportive. The upside is a ready network of mental health clinics that could adopt it, but slow rollout, strict oversight, and the need for more funding could all curb how quickly the business scales.Read more

A mental health biotech is trying to bring a guided psilocybin treatment to people who haven’t responded to existing depression therapies, and a key late-stage study milestone could speed up the road to a first launch. The upside hinges on regulators staying supportive and clinics being ready to deliver the therapy, but delays, safety concerns, or extra fundraising could quickly change the picture.Read more